Apr 28, 2022 08:00 AM

Tibet Rhodiola Pharmaceutical Holding Co.,Ltd.’s Net Profit Rose 11.2% in First Quarter of 2022

By Caixin Automation

Tibet Rhodiola Pharmaceutical Holding Co.,Ltd. (西藏诺迪康药业股份有限公司) (600211.SH) reported a net profit of 176.2 million yuan in the first quarter of 2022, up 11.2% year-on-year.

Meanwhile, the company posted 656.1 million yuan in revenue, up 32.7% year-on-year.

At the end of the reporting period, it had 4 billion yuan in total assets and 1.2 billion yuan in total liabilities, with a liability-to-asset ratio of 30.2%.

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Innovation Takes Off at Flying Vehicle Expo

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: How China’s Crypto Ban Makes Disposing of Seized Assets a Lot Harder

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s Factory Exodus Is Turning Vietnam Into the World’s Assembler

2: Meituan Enters Open-Source AI Race With LongCat Model

3: Ex-UBS Banker in Hong Kong Jailed 10 Years for Laundering $17.2 Million

4: Alipay Fined by Luxembourg Regulator for Anti-Money Laundering Breaches

5: End of U.S. Tax Exemption Hits Chinese Air Cargo Carriers Differently

SPONSORED

OR